Bioptimus Launches M-Optimus, Revolutionizing AI in Biology

Bioptimus has unveiled M-Optimus, a groundbreaking model designed to integrate various biological modalities, marking a significant advancement in AI-powered biomedical innovation. The announcement was made on December 17, 2025, in Paris, where the company emphasized that M-Optimus aims to transform how biology is understood and simulated, potentially impacting patient healthcare and biological research.

Traditional approaches to biological research have often been limited, focusing on isolated data types such as genetic sequences or medical imaging. This fragmentation has also affected healthcare delivery. With M-Optimus, Bioptimus seeks to provide a comprehensive framework that captures the interdependent complexity of biology, facilitating advancements in every phase of biological discovery and patient care.

The initial version of M-Optimus integrates a variety of biological modalities, including hematoxylin and eosin (H&E) stained histology images, bulk RNA sequencing, spatial transcriptomics, and clinical data. This innovative model is the first of its kind to combine multiple biological modalities at such an extensive scale. Trained on one of the largest proprietary datasets, which comprises millions of patients and covers more than 50 organ types from hundreds of medical centers, M-Optimus is positioned to redefine the biomedical landscape.

Applications and Early Access Opportunities

The potential applications of M-Optimus span the entire biomedical spectrum, offering significant advancements in diagnostics, drug discovery, and clinical practice. Currently, Bioptimus provides early access to a select group of pioneer clients, including top pharmaceutical companies, allowing them to leverage this powerful model in their core research workflows.

Jean-Philippe Vert, CEO and co-founder of Bioptimus, stated, “With M-Optimus, we have successfully assembled the first critical components of our journey to crack the code of biology by combining multiple modalities at scale. This early access program is designed to partner with first-mover companies who share our vision: to translate this raw scientific power into tangible breakthroughs that ultimately improve patient outcomes and revolutionize the delivery of healthcare.”

Continuing Leadership with H-Optimus-1

Alongside the launch of M-Optimus, Bioptimus continues to lead in AI models for histopathology with its H-Optimus-1 model. Recognized as a state-of-the-art tool, H-Optimus-1 is trained on millions of whole-slide images, offering top-tier performance in cancer grading and biomarker detection. With nearly one million downloads, Bioptimus has partnered with Amazon SageMaker AI to enhance the accessibility of H-Optimus-1, enabling industry professionals to implement this powerful pathology model directly within their secure cloud environments.

Bioptimus’s efforts are supported by strategic collaborations with notable organizations including AWS, HuggingFace, NVIDIA, Owkin, and Proscia. The company’s team, made up of over 50% PhDs from prestigious institutions such as MIT, ETH, ENS, and TUM, continues to push the boundaries of AI in biological understanding.

As a pioneer in the AI biotech sector, Bioptimus is dedicated to establishing a universal foundation model for biology. By merging advanced AI capabilities with extensive multimodal data generation, the company aims to create a cohesive framework that links various scales of biology, from molecular to patient levels, providing actionable insights that can drive significant advancements in healthcare.

For more information about Bioptimus and its innovative solutions, visit their website at www.bioptimus.com.